Drug intelligence / Profile preview

QL1209 + docetaxel + trastuzumab

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of QL1209 (pertuzumab biosimilar), docetaxel, and trastuzumab used for the neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer. This regimen has demonstrated equivalent efficacy and safety to reference pertuzumab + docetaxel + trastuzumab in clinical trials.

Targets

HER2 ECD II (Human epidermal growth factor receptor 2 domain II)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on QL1209 + docetaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL1209 + docetaxel + trastuzumab.

Explore the full profile